Abstract
Weinblatt and colleagues have studied the efficacy and safety of etanercept 50 mg twice weekly in comparison with etanercept 50 mg once weekly in patients with longstanding rheumatoid arthritis. The study failed to demonstrate any clinically meaningful or statistically significant benefit of the use of the twice weekly dosage. There was also a suggestion that the incidence of certain toxic effects, including sepsis, could be greater in patients receiving the twice weekly dosage, although the numbers of adverse events reported were too small to reach firm conclusions regarding additional toxicity of this higher dose. In the absence of a larger and longer-term investigation, the results of this investigation indicate that increasing the dose of etanercept beyond 50 mg weekly is not advantageous and suggest that an increased dose could be more dangerous for patients with rheumatoid arthritis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Weinblatt ME et al. (2008) Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 58: 1921–1930
Van Gestel AM et al. (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 39: 34–40
Dervieux T et al. (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50: 2766–2774
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JM Kremer has been a consultant for and received speakers' fees and grant/research support from Amgen and Wyeth.
Rights and permissions
About this article
Cite this article
Kremer, J. Etanercept for patients with RA: more is not always better. Nat Rev Rheumatol 5, 10–11 (2009). https://doi.org/10.1038/ncprheum0936
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0936